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Vitamin K has been widely promoted as a supplement for decreasing bone loss in
postmenopausal women, but the long-term benefits and potential harms are unknown. This
study was conducted to determine whether daily high-dose vitamin K1 supplementation safely
reduces bone loss, bone turnover, and fractures.
Methods and Findings
This single-center study was designed as a 2-y randomized, placebo-controlled, double-blind
trial, extended for earlier participants for up to an additional 2 y because of interest in long-
term safety and fractures. A total of 440 postmenopausal women with osteopenia were
randomized to either 5 mg of vitamin K1 or placebo daily. Primary outcomes were changes in
BMD at the lumbar spine and total hip at 2 y. Secondary outcomes included changes in BMD at
other sites and other time points, bone turnover markers, height, fractures, adverse effects, and
health-related quality of life. This study has a power of 90% to detect 3% differences in BMD
between the two groups. The women in this study were vitamin D replete, with a mean serum
25-hydroxyvitamin D level of 77 nmol/l at baseline. Over 2 y, BMD decreased by  1.28% and
 1.22% (p ¼ 0.84) (difference of  0.06%; 95% confidence interval [CI]  0.67% to 0.54%) at the
lumbar spine and 0.69% and 0.88% (p¼0.51) (difference of 0.19%; 95% CI 0.37% to 0.75%)
at the total hip in the vitamin K and placebo groups, respectively. There were no significant
differences in changes in BMD at any site between the two groups over the 2- to 4-y period.
Daily vitamin K1 supplementation increased serum vitamin K1 levels by 10-fold, and decreased
the percentage of undercarboxylated osteocalcin and total osteocalcin levels (bone formation
marker). However, C-telopeptide levels (bone resorption marker) were not significantly different
between the two groups. Fewer women in the vitamin K group had clinical fractures (nine
versus 20, p ¼ 0.04) and fewer had cancers (three versus 12, p ¼ 0.02). Vitamin K supplements
were well-tolerated over the 4-y period. There were no significant differences in adverse effects
or health-related quality of life between the two groups. The study was not powered to
examine fractures or cancers, and their numbers were small.
Conclusions
Daily 5 mg of vitamin K1 supplementation for 2 to 4 y does not protect against age-related
decline in BMD, but may protect against fractures and cancers in postmenopausal women with
osteopenia. More studies are needed to further examine the effect of vitamin K on fractures
and cancers.
Trial registration: ClinicalTrials.gov (#NCT00150969) and Current Controlled Trials
(#ISRCTN61708241)
The Editors’ Summary of this article follows the references.
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Vitamin K is best known for its function in the blood
coagulation pathway, but recent data suggest that the K
vitamins play an important role in bone metabolism, perhaps
at serum levels higher than those required for normal blood
coagulation. Vitamin K is the essential cofactor for the
carboxylation of glutamate to gamma-carboxyglutamic acid
(Gla), which confers functionality to vitamin K–dependent
Gla-containing proteins. Three Gla-containing bone proteins,
all synthesized by osteoblasts, have been identiﬁed: osteocal-
cin, matrix Gla protein, and protein S. The K vitamin family
has ﬁve groups: vitamins K1 (phylloquinone) and K2
(menaquinones) occur naturally in foods, whereas K3, K4,
and K5 are synthetic.
Over the past 5 y, vitamin K supplements have been widely
promoted by the lay media for increasing bone mass. These
supplements have also been touted to prevent heart disease
and cancer [1,2]. Vitamin K2 is an approved treatment for
osteoporosis in Japan. Low-dose vitamin K1 is currently
available in health food stores and over the Internet across
the United States and Canada. Although earlier epidemio-
logic studies showed low vitamin K1 intake and low plasma
vitamin K1 levels to be associated with low bone mineral
density (BMD) [3,4] and increased osteoporotic fracture risk
in postmenopausal women [5–8], more recent randomized
trials using low-dose vitamin K1 supplements showed con-
ﬂicting results on BMD [9–12]. None has been designed to
examine the effect of vitamin K1 supplementation on
fractures. Thus, the question of whether daily vitamin K1
supplementation reduces bone loss or decreases fracture risk
remains controversial.
We conducted a 2- to 4-y randomized, placebo-controlled,
double-blind study for the Evaluation of the Clinical use of
vitamin K supplementation in postmenopausal women with
Osteopenia (the ECKO trial). We chose 5 mg of vitamin K1
daily because previous data suggest that 1 mg daily is needed
to maximally carboxylate osteocalcin [13], that maximal
carboxylation of matrix Gla protein may require more than
1 mg daily, and that 10 mg daily for more than 3 mo was safe
with no signiﬁcant adverse effects [14]. At the time of
planning for this study, we were also aware of two other
low-dose vitamin K1 supplementation trials—one using 1 mg
[10] and the other using 500 lg [9] of vitamin K1 daily. We
decided to use a much higher dose so that the results from
our study would complement those from the other two
studies. Our primary objectives were to determine the effects
of daily vitamin K1 supplementation on BMDs at the lumbar
spine and total hip at 2 y. Our hypothesis was that vitamin K1
supplementation would reduce bone loss in postmenopausal
women at those sites over a 2-y period. Our secondary
objectives were to investigate the effects of vitamin K1
supplementation on BMDs at the femoral neck and the
ultradistal radius and at other time points, bone turnover
markers, change in height, fractures, and long-term adverse
effects on health and health-related quality of life.
Methods
Design Overview
This study was originally designed as a 2-y single-center,
randomized, double-blind, placebo-controlled trial of daily
oral supplementation of vitamin K1 (5 mg) versus placebo
(see Text S1 and S3). Because of considerable interest over
the past few years in the long-term safety and efﬁcacy of
vitamin K on fractures, we extended our study for up to 4 y of
supplementation in women who joined the study earlier (see
Text S2 and S3). Speciﬁcally, we invited all participants who
started the study prior to 15 March 2004 to join the extension
study for a duration of 6–24 mo, so that their ﬁnal study visit
date was no later than 30 September 2006.
We obtained an investigational new drug number from
Health Canada on 31 December 2001 for this study.
Postmenopausal women were recruited through health fairs,
advertisements, and posters from January 2002 to September
2004. All women gave written informed consent prior to any
study procedures. They were examined annually at the
University Health Network according to International Com-
mittee on Harmonization (ICH) good clinical practice guide-
lines. Outcome and safety data collection were completed by
30 October 2006, and 2 March 2007, respectively, and
unblinding occurred on 8 March 2007. Compliance was
assessed by counting leftover pills at follow-up visits by two
study staff members who were working independently and
blinded to treatment assignment. Participants taking 80% or
more of the prescribed study pills were considered compliant.
The protocol was approved by the University Health Network
(UHN) and the University of Toronto research ethics boards.
Study Participants
We chose postmenopausal women with osteopenia as our
study population because they are at increased risk of
developing osteoporosis and fractures. Women were eligible
to participate in the study if they were postmenopausal (at
least 1 y after last menses) and had their lowest t-score
(lumbar spine [L1–L4], total hip, or femoral neck) between
 1.0 and 2.0. They were excluded if they had osteoporosis; a
fragility fracture after age 40; any bone medication use in the
past 3 mo (such as bisphosphonates, selective estrogen
receptor modulators, hormone replacement therapy, or
calcitonin); any bisphosphonate use for more than 6 mo;
known metabolic bone diseases such as primary hyper-
parathyroidism or Paget disease; decompensated diseases of
the liver, kidney, pancreas, lung, or heart; history of active
cancer in the past 5 y; or chronic oral steroid or warfarin use.
They were also excluded if they were on high doses of vitamin
A( .10,000 IU/d) or E (.400 IU/d), as these interfere with
vitamin K metabolism [15].
Interventions and Randomization
Both vitamin K1 and placebo pills were manufactured by
Tishcon to look and taste the same. The UHN research
pharmacy labeled and dispensed study pills according to a
computer-generated random number table in blocks of ten.
Participants, study coordinators, investigators, and outcome
assessors were all blinded to the assignment. Participants
were asked to take their study pill in the morning with food.
They were also given calcium and vitamin D supplements that
approximated a total intake (diet plus supplements) of 1,500
mg of calcium and 800 IU of vitamin D per day.
Outcomes and Follow-up
PrimaryoutcomemeasureswerepercentagechangeinBMD
at the lumbar spine (L1–L4) and total hip from baseline to 2 y.
Secondary outcome measures included BMD at the femoral
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and resorption (C-terminal telopeptide, CTX) markers,
fractures, height, percentage of undercarboxylated osteocal-
cin (ucOC) and serum vitamin K levels (measures of vitamin K
status), adverse effects, and health-related quality of life.
BMD at the lumbar spine, total hip, femoral neck, and
ultradistal radius were measured yearly, and vertebral
fracture assessment (VFA) was performed at baseline, 24,
and 48 mo, or at ﬁnal visit. Tests were performed according
to standard protocol using one Hologic 4500A densitometer
at the UHN Bone Density Laboratory. Both the technologist
and the BMD densitometrist (YL) were certiﬁed by the
International Society of Clinical Densitometry, not involved
in the care of study participants, and blinded to treatment
assignment. Women were discontinued from the study if their
annual BMD T-score at the lumbar spine, femoral neck, or
total hip fell below 2.5; they were not allowed to participate
in the study extension if their BMDs dropped more than 10%
over 2 y. The coefﬁcients of variation (CVs) for BMD at the
lumbar spine and total hip were 0.89% and 1.09%,
respectively. Using the valid and reliable Genant semi-
quantitative method for assessing morphometric vertebral
fractures [16], vertebrae were graded as normal, Grade 1
(20%–25% decrease in height), Grade 2 (25%–40%), or Grade
3( .40%). We deﬁned a new morphometric fracture as a
deformity occurring in a normal vertebra or a worsening
grade of deformity during the study period.
Reported clinical fractures were conﬁrmed by radiographs
or radiological reports, adjudicated by two investigators (GH
and RJ) independently and classiﬁed into fragility (sustained
with minimal trauma such as falling from standing height) or
nonfragility fractures. A third investigator (SJ) resolved
differences in cases of discordance. The a priori fracture
outcomes included all clinical fractures (except ﬁngers and
toes) and all new morphometric vertebral fractures. We also
measured height using a Harpenden stadiometer and health-
related quality of life using the Medical Outcomes Study 36-
item Short-Form General Health Survey (SF-36) [17,18].
We asked our participants to inform us of any new medical
condition, hospitalization, or symptom they experienced
during the study. In addition, at every study visit (baseline,
3, 6, 12, 18, 24, 30, 36, 42, and 48 mo), participants were asked
about their health and any new medications or change in
medications during the intervening months. All these
symptoms, medications, and conditions were collected in a
standardized fashion. Serious adverse events (SAEs) are
deﬁned as any hospitalizations, cancer, life-threatening
events, or death. We used the standard deﬁnition according
to the ICH Guidelines for the Conduct of Clinical Trials.
Adverse events (AEs) are deﬁned as any untoward effect
experienced by the participant that are not considered an
SAE. All the AEs and SAEs were coded by a physician blinded
to study group assignment using ICD-9 (International
Statistical Classiﬁcation of Diseases and Related Health
Problems, ninth revision) codes. We requested backup
medical records including pathological reports and death
certiﬁcates for all SAEs, and these were adjudicated by two
blinded physician reviewers. All SAEs and AEs with cumu-
lative incidence of greater than 1% in either the vitamin K or
the placebo group were analyzed to see if there were
differences between groups.
Serum was collected in the morning after an overnight fast
at baseline, 3, 12, 24, 36, and 48 mo, stored in a 80 8C freezer,
and analyzed in batches at the end of the study. Aliquots for
ucOC (treated with hydroxyapatite) [19] and OC were run
side-by-side using the N-Mid Osteocalcin electrochemilumi-
nescent assay, and CTX was measured using the B-Crosslaps
assay (Elecsys 2010 Immunochemistry Auto-analyzer, Roche
Diagnostics, Germany). Intra-assay and inter-assay variability
were 0%–2.5% and 1%–2.5% for OC and 0.1%–3.5% and
2.2%–3.1% for CTX, respectively. The percentage of ucOC
was expressed as the ratio of ucOC to OC multiplied by 100.
Serum vitamin K levels were measured in the Tufts University
Vitamin K laboratory using reversed-phase high-performance
liquid chromatography with postcolumn, solid-phase chem-
ical reduction of phylloquinone to its hydroquinone, followed
by ﬂuorometric detection [20]. The CV of the vitamin K1
assay was 5.3%. The estimated limits of detection for vitamin
K1, menaquinone 4, and menaquinone 7 were 0.08 pmol, 0.07
pmol, and 0.40 pmol per injection, respectively. Serum 25-
hydroxyvitamin D levels were measured in the UHN clinical
laboratory using the radioimmunoassay method (Diasorin,
Stillwater, MN). The inter-assay CV was 9.5%–11.5% over the
study period.
Statistical Analyses
All analyses in this article were prespeciﬁed and ﬁnalized
by 30 November 2006, prior to any analysis and prior to
unblinding on 8 March 2007. For our 2-y BMD analyses, we
included all 440 women based on intention to treat using last
observation carried forward for missing data. Analyses of all
other outcomes, including comparisons of BMD beyond 2 y,
used only observed values. The main test statistic was the two-
sample t-test. In sensitivity analyses, we used analysis of
covariance to control for any dependence of change on
baseline values. We also analyzed our data according to
compliance and serum vitamin K and 25-hydroxyvitamin D
levels by looking for a statistical interaction between groups
and using linear regression models with the various 2-y
outcomes.
We used the log-rank test and survival analysis techniques
to examine the effect of vitamin K supplementation on
fracture and cancer incidence. Time was deﬁned as number
of days from randomization to the ﬁrst endpoint (if one
occurred), death, or date of last contact. Kaplan-Meier plots
were used to graphically explore event-free survival. Cox
proportional hazards models were used to compare the
effects of vitamin K and placebo. We also investigated
whether mean serum vitamin K levels over the ﬁrst 2 y had
any relationship to fracture or cancer incidence.
Based on preliminary estimates of standard deviations in
BMD at the lumbar spine and total hip in postmenopausal
women with osteopenia, we determined that 200 participants
were required in each group for the study to have a statistical
power of 80% to detect clinically meaningful differences of
3% between treatment groups while allowing for a projected
10% withdrawal and 5% lost to follow-up rate per year. We
over-recruited to 440, resulting in a power of 90%.
Results
Baseline Characteristics
We screened 6,587 women and invited 848 to our center
for a screening visit (Figure 1). Of those, 440 postmenopausal
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Vitamin K in Postmenopausal Osteopenic WomenFigure 1. Flowchart of the ECKO Trial showing Participation of Women in the Study
This flow diagram shows the number of study participants remaining in the study at each time point. *Women were not invited to participate in study
extension if they were enrolled after 15 March 2004. **Participation was terminated for these women because the study was terminated. All final visits
occurred between March and October 2006.
doi:10.1371/journal.pmed.0050196.g001
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criteria were randomly assigned to 5 mg of vitamin K1 daily
(217 women) or placebo (223 women). Three others were
inadvertently randomized (one woman with hyperthyroidism,
one who was perimenopausal, and one with a small breast
mass at screening that was subsequently diagnosed as breast
cancer); these women were excluded from all analyses.
Baseline characteristics of the two groups were similar (Table
1). Mean age of participants was 59 y (range 40 to 82), and
88% were European Canadian. Mean baseline serum 25-
hydroxyvitamin D level was 77 nmol/l. At 2 y, 402 women
(91.4%) had active follow-up, and 363 (83.2%) were compliant
(82.5% in the vitamin K group and 83.9% in the placebo
group). Of the women who joined the study prior to 15 March
2004, a total of 261 women (121 on vitamin K, 140 on placebo)
consented to participate in the study extension. There was no
difference in baseline characteristics between the two groups,
and there was no difference in baseline characteristics
between those who participated in the extension and those
who did not. During the study extension, 87.5% (84.9% in the
vitamin K group and 89.9% in the placebo group) and 88.6%
(82.4% in the vitamin K group and 93.3% in the placebo
group) were compliant at 3 and 4 y, respectively.
Bone Mineral Densities, Turnover Markers, and Fractures
In the vitamin K and placebo groups, respectively, BMD
decreased by  1.28% and  1.22% (p ¼ 0.84) (difference of
 0.06%; 95% conﬁdence interval [CI],  0.67% to 0.54%) at
the lumbar spine and  0.69% and  0.88% (p ¼ 0.51)
(difference of 0.19%; 95% CI  0.37% to 0.75%) at the total
hip over 2 y. With the exception of a 1.7% difference in BMD
at the femoral neck between the two groups at 36 mo, the
changes in BMDs at the lumbar spine, total hip, femoral neck,
and ultradistal radius were similar over the 2- to 4-y
treatment period (Figure 2). Results did not change when
we controlled for baseline BMD values or compliance.
At 2 y, serum total OC levels decreased (21 ng/ml versus 24
ng/ml, p , 0.0001) in women supplemented with vitamin K
compared to placebo, but serum CTX levels were similar
between groups (0.58 ng/ml versus 0.54 ng/ml, p¼0.07) (Figure
3). Although the difference in mean CTX levels between the
two groups was statistically signiﬁcant at 12 mo, the differ-
ences at other time points were not. In addition, most of these
differences were not of clinically meaningful magnitudes.
During the study and follow-up period, 32 clinical fractures
were sustained by 29 women: nine women in the vitamin K
group (three radius, one vertebra, one rib, three knees [tibial
plateau, patella, subchondral], two feet [metatarsal and
cuboid], and one ankle [tip of ﬁbula]) and 20 women in the
placebo group (nine radius, two humerus, one clavicle, one
hip, one tibia, four foot, two ankles [bimalleolar, ﬁbula], and
one hand) (hazard ratio [HR] ¼ 0.41, 95% CI 0.15 to 1.18, p ¼
0.08 at 2 y and HR¼0.45, 95% CI 0.20 to 0.98, p¼0.04 at 4 y)
(Figure 4A). Of these 32 clinical fractures, 17 were considered
Table 1. Baseline Characteristics of Women Participating in the ECKO Trial
Characteristics Category Vitamin K (n ¼ 217) Placebo (n ¼ 223)
Age, mean (range) — 58.9 (40.1–80 5) 59.2 (46.1–82.3)
Age at menarche, mean (range) — 12.8 (9–17) 12.7 ( 9–17)
Age of menopause, mean (range) Natural menopause 50.0 (20–62) 50.4 (36–64)
Surgical menopause 41.7 (26–55) 43.3 (28–54)
Years since menopause, mean (SD) — 10.5 (8.3) 10.0 (8 2)
BMI (kg/cm
2), mean (SD) — 26.1 (4.6) 26.2 (4 4)
Ethnicity, n (%): European Canadian 191 (88.0%) 197 (88.3%)
Asian 15 ( 6.9%) 16 ( 7.2%)
African Canadian 7 ( 3.2%) 8 ( 3.6%)
Other 4 ( 1.8%) 2 ( 0.9%)
Education, n (%) High school or less 46 (21.2%) 41 (18.4%)
Community college 51 (23.5%) 53 (23.8%)
University 80 (36.9%) 85 (38.1%)
Postgraduate 40 (18.4%) 44 (19.7%)
Marital status. n (%) Single/divorced 93 (42.9%) 102 (45.7%)
Married/common-law 124 (57.1%) 121 (54.3%)
Family osteoporosis history, n (%) — 77 (35.8%) 71 (32.4%)
Smoking, n (%) Current smoker 13 ( 6.0%) 13 ( 5.8%)
Previous smoker 96 (44.2%) 108 (48.4%)
Alcohol use, n (%)   1serving/d 196 (90.3%) 192 (86.1%)
. 1 serving/d 21 (9.7%) 31 (13.9%)
Bone mineral density, mean (SD) (g/cm
2) Spine L1–L4 0.922 (0.110) 0.924 (0.079)
Total hip 0.862 (0.080) 0.879 (0.080)
Femoral neck 0.711 (0.066) 0.717 (0.066)
Ultra distal radius 0.403 (0.046) 0.411 (0.053)
HRT use, n (%) Previous HRT use 99 (45.6%) 99 (44.4%)
Discontinued within 1 y 25 (11.5%) 28 (12.6%)
Bone turnover markers, mean (SD) (ng/ml) Serum total osteocalcin 25.1 (7.9) 24.5 (8.6)
Serum CTX 0.6 (0.2) 0.6 (0.2)
Vitamin K status, mean (SD) Serum vitamin K (nmol/l) 1.8 (1.8) 1.8 (1.9)
Percentage of undercarboxylated osteocalcin (%) 44.8 (8.6) 46.4 (8.9)
25-OH vitamin D, mean (SD) (nmol/l) — 75.8 (23.6) 77.7 (26.7)
SD, standard deviation.
doi:10.1371/journal.pmed.0050196.t001
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Vitamin K in Postmenopausal Osteopenic WomenFigure 2. Changes in Bone Mineral Density over Time
These graphs show mean percentage change from baseline (D) in bone mineral densities at the lumbar spine (L1–L4), total hip, femoral neck, and
ultradistal radius sites in the vitamin K ( ) and placebo (*) groups over time, with their respective 95% confidence intervals. From baseline to 2 y (left
part of graphs), all 440 women were included in the analyses based on intention-to-treat principle. We used last observation carried forward for any
missing data in later visits. The analyses of the 2- to 4-y outcomes in the study extension (right part of graphs) were based on observed outcomes only.
doi:10.1371/journal.pmed.0050196.g002
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Vitamin K in Postmenopausal Osteopenic Womenfragility fractures (six fractures sustained by four women on
vitamin K and 11 fractures sustained by ten women on
placebo, p ¼ 0.11). A total of 47 women had new morpho-
metric vertebral fractures on VFA (most were Grade 1
fractures): 25 in the vitamin K group and 22 in the placebo
group (p¼0.56). There was no difference in mean changes in
height between groups.
Relationship between Serum Vitamin K, Vitamin D levels,
and BMD and Fractures
Daily 5 mg of vitamin K1 supplementation increased serum
vitamin K1 levels (22.6 nmol/l versus 2.0 nmol/l, p , 0.0001 at
2 y) (Figure 3D), but did not increase circulating vitamin K2
(menaquinones 4 and 7) levels. Vitamin K1 supplementation
Figure 3. Changes in Biochemical Markers of Bone Turnover and Vitamin K Status Over Time
These graphs showed mean total OC levels (bone formation marker), mean CTX (bone resorption marker), mean change in percentage of ucOC, and
mean serum vitamin K levels in the vitamin K ( ) and placebo (*) groups over time, with their respective 95% confidence intervals. All analyses were
performed using observed outcomes. Because of limited study budget, we analyzed baseline and 2-y serum vitamin K levels in almost all the
participants, but only a random sample at the other time points for those in the vitamin K group and none in the placebo group beyond 2 y.
doi:10.1371/journal.pmed.0050196.g003
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Vitamin K in Postmenopausal Osteopenic Womendecreased ucOC and percentage of ucOC ( 52.8% versus
 3.5%, p , 0.0001, and 21.4% versus 2.0%, p , 0.0001 at 2
y, respectively) (Figure 3C). Serum vitamin K1 and serum 25-
hydroxyvitamin D levels were not related to percentage
change in BMD, CTX, or fractures. There was also no
relationship between these outcomes and the interaction of
serum vitamin K1 and 25-hydroxyvitamin D levels.
Adverse Effects and Health-Related Quality of Life
Oneormoreadverseeventswereexperiencedby384women
(87.3%) during the ﬁrst 2 y of the study, but there were no
signiﬁcant differences between groups. Nausea and vomiting
were reported in 11 women (5.1%) on vitamin K and ten
women (4.5%) on placebo (p¼0.77). From 2 to 4 y, 69.6% (188/
270) had one or more adverse event: 72.2% (91/126) in the
vitamin K group and 67.4% (97/144) on placebo (p¼0.46).
SAEs occurred in 9.1% (40/440) of participants: 6.9% (15/
217) in the vitamin K group and 11.2% (25/223) in the placebo
group. These included hospitalizations for pneumonia, heart
failure, gastrointestinal bleeding, elective and nonelective
surgeries, cancer, and death. Cancer incidence was lower in
the vitamin K group than in the placebo group (three versus
12, p ¼ 0.02; HR ¼ 0.25, 95% CI 0.07 to 0.89) (Figure 4B).
Higher mean serum vitamin K levels over the duration of the
study correlated with lower cancer incidence (p , 0.05)
(Figure 4C). Because half of the cases were breast cancers (one
in the vitamin K group and six in the placebo group), we
calculated the Gail breast cancer risk score [21] from baseline
data and found that there was no difference between the
vitamin K and the placebo groups (1.70% versus 1.71% risk of
having invasive breast cancer in the next 5 y). There were ﬁve
deaths during the study and follow-up period: one woman on
vitamin K (passenger in a car accident) and four women on
placebo (three who died of cancers, and one who died in her
sleep from arrhythmogenic right ventricular cardiomyop-
athy). There was no difference in health-related quality of life
between groups.
Discussion
Our study showed that 5 mg of vitamin K1 supplementa-
tion daily for 2–4 y did not protect against age-related decline
in BMD at the lumbar spine, total hip, femoral neck, or
ultradistal radius in postmenopausal women with osteopenia
who were vitamin D replete. We also showed that vitamin K1
supplementation did not decrease bone resorption, but did
protect against clinical fractures and cancers. Daily supple-
mentation with high-dose vitamin K1 signiﬁcantly increased
serum vitamin K levels and decreased percentage of under-
carboxylated osteocalcin. It was very well tolerated with no
signiﬁcant adverse effects.
Our BMD data are consistent with data from four recently
published (or presented) randomized trials using much lower
doses of vitamin K1 supplements [9–12], although the
interpretation of the data differed somewhat among research
groups. Booth and colleagues randomized 452 healthy men
and women between 60 and 80 y of age to receive a
multivitamin that contained either 500 lg/d of vitamin K1
or no vitamin K1 plus a daily calcium (600 mg) and vitamin D
(400 IU) supplement [9]. After 3 y, they did not ﬁnd any
differences in BMD at the femoral neck, lumbar spine, or total
body between the two groups. The Binkley group studied 381
postmenopausal women and found that neither vitamin K1 (1
mg/d) nor vitamin K2 (45 mg/d) supplementation for 2 y
affected BMD at the lumbar spine or total hip [10].
In contrast, two earlier trials observed differences in the
femoral neck and ultradistal radius sites. Braam and
colleagues randomized 181 postmenopausal women between
50 and 60 y of age to a daily supplement containing placebo,
minerals (calcium, magnesium, and zinc), and vitamin D (320
IU/d), or minerals and vitamins D and K1 (1 mg/d) [9]. After 3
y, the group receiving vitamin K had less bone loss at the
femoral neck (BMD difference of 1.7%) but not at the lumbar
spine. In the Bolton-Smith study [10], 244 postmenopausal
women were randomized to receive placebo, vitamin K1
(200ug/d), vitamin D3 (400 IU) plus calcium (1,000 mg/d), or
vitamins K1 and D plus calcium. After 2 y, there was no
signiﬁcant difference in BMD at any site between groups;
however, the group taking the combined vitamins K, D, and
calcium showed a 1.6% increase in BMD at the ultradistal
radius site compared to baseline. Based on these data, the
authors of these two trials concluded that vitamin K1
supplementation is helpful to prevent bone loss in post-
menopausal women, especially when combined with vitamin
D and calcium. We feel that the small differences observed in
these two studies are likely due to measurement variability as
well as statistical issues, and are of little clinical signiﬁcance.
Our study showed that daily 5 mg of vitamin K1 supple-
mentation increased serum vitamin K level by approximately
10-fold, but decreased serum ucOC, percentage of ucOC and
total OC (a bone formation marker) levels. The decrease in
ucOC and percentage of ucOC reﬂect improved vitamin K
status. We do not fully understand the mechanism behind
decreased serum total OC; however, we have two hypotheses.
As more OC becomes carboxylated and functional with
improved vitamin K status, less is needed, and thus less is
synthesized and released into the circulation. The other
potential explanation for this observation is that more func-
tional OC will be bound to bone rather than circulating in the
blood stream, thus lowering the serum total OC level. This
decrease in total OC, as well as the decrease in percentage of
ucOC, has been previously described by other groups [22,23].
Similar to data from recently published studies [9,10,22],
vitamin K1 supplementation in our study did not result in a
decrease in bone resorption. Our mean serum CTX levels
were similar between the two groups at all time points except
at 12 mo. The difference observed at 12 mo is likely by
chance, as the differences at most other time points are not of
clinically signiﬁcant magnitudes.
Despite a lack of effect on BMD and bone resorption, we
observed a lower incidence of clinical fractures among
women in the vitamin K1 group, suggesting that the effect
Figure 4. Cumulative Incidence of Clinical Fractures and Cancer
The cumulative incidence of clinical fractures (A) and cancer (B) are shown for the vitamin K and placebo groups (C). The relationship of the cumulative
incidence of cancer according to tertiles of 2-y serum vitamin K levels (shown in brackets and expressed in nmol/l). When Cox regression analysis was
performed using the 2-y serum vitamin K levels as a continuous log-transformed variable, the relationship between vitamin K levels and the cumulative
incidence of cancer was statistically significant at p , 0.05.
doi:10.1371/journal.pmed.0050196.g004
PLoS Medicine | www.plosmedicine.org October 2008 | Volume 5 | Issue 10 | e196 1469
Vitamin K in Postmenopausal Osteopenic Womenof vitamin K1 on bone may not be mediated by BMD or bone
turnover. Our ﬁndings are congruent with epidemiologic
data from the Framingham Heart Study [24] and the Nurses’
Health Study [5]. A recent meta-analysis of randomized
controlled trials also showed that daily supplementation with
vitamin K2 (45 mg of menaquinone 4) consistently reduces
hip (odds ratio [OR] ¼ 0.23, 95% CI 0.12 to 0.47), vertebral
(OR ¼ 0.40, 95% CI 0.25 to 0.65), and all nonvertebral
fractures (OR ¼ 0.19, 95% CI 0.11% to 0.35) [25]. In a recent
study, Knapen and colleagues suggests that vitamin K2
supplementation improves bone strength via bone geometry
rather than BMD [26]. Whether vitamin K1 affects bone
geometry and bone quality rather than bone density, and
whether there are differences in the effects of vitamins K1
and K2 on bone remains to be determined.
We also detected a lower incidence of cancers in the
vitamin K–supplemented group. Recent data suggest that the
K vitamins may have anticancer effects [27]. Most of the data
have been on vitamin K3, especially as adjuvant therapy in
conjunction with vitamin C in the treatment of hepatocel-
lular cancer, leukemia, bladder, ovarian, prostate, and other
cancers [28,29]. There are some data on the anticancer effects
of vitamins K2 and K5 [30–34]. Our study may be the ﬁrst to
suggest that vitamin K1 also has anticancer effects. These
effects may be mediated through tyrosine kinases [27].
Our study has several limitations. It was originally designed
as a 2-y study with BMD as the primary outcome. Women
were then recruited into a study extension of variable
duration because follow-up visits were planned to terminate
between March and September 2006. Thus, the number of
women followed to 3 and 4 y was small, and the study was not
powered to examine fracture outcomes. We used densito-
metric VFA for the assessment of morphometric vertebral
fractures. VFA has been shown to be less precise than
conventional lateral spine radiography in assessing for
presence of morphometric vertebral fractures [35]. Our
results on morphometric fractures could have been inﬂu-
enced by the use of this technique. In addition, the number of
cancers observed was small, and a chance association cannot
be ruled out. However, our observed fracture and cancer
reduction is consistent with other research, reducing the
likelihood that these are just chance ﬁndings.
In conclusion, vitamin K1 supplementation at a daily dose
of 5 mg does not protect against age-related decreases in
BMD, but may reduce the incidence of fractures and cancers
in postmenopausal women with osteopenia. Additional
studies need to be conducted to understand the potential
mechanisms behind these observations. Before high-dose
vitamin K1 supplementation can be recommended for
general use, further randomized controlled trials have to be
done to conﬁrm these ﬁndings.
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Background. Osteoporosis is a bone disease in which the bones
gradually become less dense and more likely to break. In the US, 10
million people have osteoporosis and 18 million have osteopenia, a
milder condition that precedes osteoporosis. In both conditions,
insufficient new bone is made and/or too much old bone is absorbed.
Although bone appears solid and unchanging, very little bone in the
human body is more than 10 y old. Old bone is continually absorbed and
new bone built using calcium, phosphorous, and proteins. Because the
sex hormones control calcium and phosphorous deposition in the bones
and thus bone strength, the leading cause of osteoporosis in women is
reduced estrogen levels after menopause. In men, an age-related decline
in testosterone levels can cause osteoporosis. Most people discover they
have osteoporosis only when they break a bone, but the condition can
be diagnosed and monitored using bone mineral density (BMD) scans.
Treatments can slow down or reverse bone loss (antiresorptive therapies)
and some (bone formation therapies) can even make bone and build
bone tissue.
Why Was This Study Done? Although regular exercise and a healthy
diet can help to keep bones strong, other ways of preventing
osteoporosis are badly needed. Recently, the lay media has promoted
vitamin K supplements as a way to reduce bone loss in postmenopausal
women. Vitamin K (which is found mainly in leafy green vegetables) is
required for a chemical modification of proteins called carboxylation.
This modification is essential for the activity of three bone-building
proteins. In addition, there is some evidence that low bone density and
fractures are associated with a low vitamin K intake. However, little is
known about the long-term benefits or harms of vitamin K supplements.
In this study, the researchers investigate whether a high-dose daily
vitamin K supplement can safely reduce bone loss, bone turnover, and
fractures in postmenopausal women with osteopenia in a randomized
controlled trial called the ‘‘Evaluation of the Clinical Use of Vitamin K
Supplementation in Post-Menopausal Women With Osteopenia’’ (ECKO)
trial.
What Did the Researchers Do and Find? In the study, 440
postmenopausal women with osteopenia were randomized to receive
5mg of vitamin K1 (the type of vitamin K in North American food; the
recommended daily adult intake of vitamin K1 is about 0.1 mg) or an
inactive tablet (placebo) daily for 2 y; 261 of the women continued their
treatment for 2 y to gather information about the long-term effects of
vitamin K1 supplementation. All the women had regular bone density
scans of their lower back and hips and were examined for fractures and
for changes in bone turnover. After 2 y and after 4 y, lower back and hip
bone density measurements had decreased by similar amounts in both
treatment groups. The women who took vitamin K1 had 10-fold higher
amounts of vitamin K1 in their blood than the women who took placebo
and lower amounts of a bone formation marker; the levels of a bone
resorption marker were similar in both groups. Over the 4-y period, fewer
women in the vitamin K group had fractures (nine versus 20 women in
the placebo group), and fewer had cancer (three versus 12). Finally,
vitamin K supplementation was well tolerated over the 4-y period and
adverse health effects were similar in the two treatment groups.
What Do These Findings Mean? These findings indicate that a high
daily dose of vitamin K1 provides no protection against the age-related
decline in bone density in postmenopausal women with osteopenia, but
that vitamin K1 supplementation may protect against fractures and
cancers in these women. The apparent contradiction between the effects
of vitamin K1 on bone density and on fractures could mean that vitamin
K1 supplements strengthen bone by changing factors other than bone
density, e.g., by changing its fine structure rather than making it denser.
However, because so few study participants had fractures, the difference
in the fracture rate between the two treatment groups might have
occurred by chance. Larger studies are therefore needed to examine the
effect of vitamin K1 on fractures (and on cancer) and, until these are
done, high-dose vitamin K1 supplementation should not be recom-
mended for the prevention of osteoporosis.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050196.
  The US National Institute of Arthritis and Musculoskeletal and Skin
Diseases provides detailed information about osteoporosis (in English
and Spanish) and links to other resources, including an interactive web
tool called Check Up On Your Bones
  MedlinePlus provides links to additional information about
osteoporosis (in English and Spanish)
  The MedlinePlus Encyclopedia has a page about vitamin K
  The UK Food Standards Agency provides information about vitamin K
  Full details about the ECKO trial are available on the ClinicalTrials.gov
Web site
  The Canadian Task Force for Preventive Health Care provides
recommendations on the prevention of osteoporosis and osteoporotic
fractures in postmenopausal women
  Osteoporosis Canada provides information on current topics related to
osteoporosis
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